Peter Mattar, MD
Family Medicine · Fontana, CANPI 1417005422
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations.
Across 81 payments — averaging $21.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$268
- Lilly USA, LLC$236
- AbbVie$213
- Merck$153
- Boston Scientific$139
- Dexcom, Inc.$137
- plus $625 from 16 others
Across 106 payments — averaging $21,377 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.3M
- Pacira Therapeutics, Inc.$562K
- Organogenesis Inc.$157K
- Welch Allyn$102K
- Anika Therapeutics, Inc.$58K
- Sun Pharmaceutical Industries Inc.$51K
- plus $73K from 6 others
What the payments were for
- Food & beverage$1,770100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $268 |
| Lilly USA, LLC | 10 | $236 |
| AbbVie | 8 | $213 |
| Merck | 8 | $153 |
| Boston Scientific | 2 | $139 |
| Dexcom, Inc. | 7 | $137 |
| Biohaven Pharmaceuticals, Inc. | 5 | $92 |
| Boehringer Ingelheim | 3 | $65 |
| Pfizer | 4 | $61 |
| AstraZeneca | 3 | $53 |
| GSK | 2 | $50 |
| Astellas Pharma US Inc | 2 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $44 |
| Optos, Inc. | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Amgen | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Medtronic | 1 | $22 |
| Nevro Corp. | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $16 |
| Covis Pharma GmbH | 1 | $14 |
How this compares
$1,770 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega HafyeraPaliperidone Palmitate | 25 | $520,989 |
| CreonLipase/Protease/Amylase | 32 | $280,166 |
| EliquisApixaban | 82 | $72,564 |
| FarxigaDapagliflozin Propanediol | 30 | $26,671 |
| JardianceEmpagliflozin | 31 | $25,409 |
| EntrestoSacubitril/Valsartan | 13 | $18,159 |
| JanuviaSitagliptin Phosphate | 22 | $16,357 |
| XareltoRivaroxaban | 13 | $13,284 |
| TrulicityDulaglutide | 11 | $10,206 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,667 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $4,478 |
| Lacosamide | 11 | $4,274 |
| Atorvastatin Calcium | 462 | $4,228 |
| Levothyroxine Sodium | 266 | $3,516 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 16 | $2,425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $213 | $280,16632 claims |
| PfizerEliquis | $61 | $72,56482 claims |
| AstraZenecaFarxiga | $53 | $26,67130 claims |
| Boehringer IngelheimJardiance | $65 | $25,40931 claims |
| MerckJanuvia | $153 | $16,35722 claims |
| Lilly USA, LLCTrulicity, Humulin 70-30 | $236 | $12,63127 claims |
| GSKBreo Ellipta | $50 | $6,66713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.
Other family medicine in Fontana
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.